دورية أكاديمية
Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia.
| العنوان: | Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia. |
|---|---|
| المؤلفون: | K Bhanumathy K; Division of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada., Balagopal A; Division of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada., Vizeacoumar FS; Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada., Vizeacoumar FJ; Division of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.; Cancer Research Department, Saskatchewan Cancer Agency, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada., Freywald A; Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada., Giambra V; Institute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, FG, Italy. |
| المصدر: | Cancers [Cancers (Basel)] 2021 Jan 07; Vol. 13 (2). Date of Electronic Publication: 2021 Jan 07. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
| مستخلص: | Protein kinases constitute a large group of enzymes catalysing protein phosphorylation and controlling multiple signalling events. The human protein kinase superfamily consists of 518 members and represents a complicated system with intricate internal and external interactions. Protein kinases are classified into two main families based on the ability to phosphorylate either tyrosine or serine and threonine residues. Among the 90 tyrosine kinase genes, 58 are receptor types classified into 20 groups and 32 are of the nonreceptor types distributed into 10 groups. Tyrosine kinases execute their biological functions by controlling a variety of cellular responses, such as cell division, metabolism, migration, cell-cell and cell matrix adhesion, cell survival and apoptosis. Over the last 30 years, a major focus of research has been directed towards cancer-associated tyrosine kinases owing to their critical contributions to the development and aggressiveness of human malignancies through the pathological effects on cell behaviour. Leukaemia represents a heterogeneous group of haematological malignancies, characterised by an uncontrolled proliferation of undifferentiated hematopoietic cells or leukaemia blasts, mostly derived from bone marrow. They are usually classified as chronic or acute, depending on the rates of their progression, as well as myeloid or lymphoblastic, according to the type of blood cells involved. Overall, these malignancies are relatively common amongst both children and adults. In malignant haematopoiesis, multiple tyrosine kinases of both receptor and nonreceptor types, including AXL receptor tyrosine kinase (AXL), Discoidin domain receptor 1 (DDR1), Vascular endothelial growth factor receptor (VEGFR), Fibroblast growth factor receptor (FGFR), Mesenchymal-epithelial transition factor (MET), proto-oncogene c-Src (SRC), Spleen tyrosine kinase (SYK) and pro-oncogenic Abelson tyrosine-protein kinase 1 (ABL1) mutants, are implicated in the pathogenesis and drug resistance of practically all types of leukaemia. The role of ABL1 kinase mutants and their therapeutic inhibitors have been extensively analysed in scientific literature, and therefore, in this review, we provide insights into the impact and mechanism of action of other tyrosine kinases involved in the development and progression of human leukaemia and discuss the currently available and emerging treatment options based on targeting these molecules. |
| References: | ACS Chem Biol. 2018 Jun 15;13(6):1551-1559. (PMID: 29763550) Growth Factors. 2000;18(1):63-78. (PMID: 10831073) Blood. 2002 Sep 1;100(5):1532-42. (PMID: 12176867) Science. 1998 Jan 23;279(5350):577-80. (PMID: 9438854) Mol Cancer. 2018 Feb 19;17(1):49. (PMID: 29455643) Med Pediatr Oncol. 1999 Dec;33(6):525-9. (PMID: 10573574) J Clin Invest. 2005 Feb;115(2):369-78. (PMID: 15650771) Blood. 2010 Mar 25;115(12):2412-9. (PMID: 20061560) Leukemia. 2008 Jun;22(6):1139-43. (PMID: 18401419) Clin Cancer Res. 2002 May;8(5):935-42. (PMID: 12006504) Oncogene. 2000 Nov 20;19(49):5636-42. (PMID: 11114744) Cancer Cell. 2014 Feb 10;25(2):226-42. (PMID: 24525236) Science. 2002 Dec 6;298(5600):1912-34. (PMID: 12471243) Blood. 2010 Mar 25;115(12):2372-9. (PMID: 20056794) Haematologica. 2005 Jul;90(7):949-68. (PMID: 15996933) Blood Adv. 2020 Jul 14;4(13):3000-3010. (PMID: 32614965) Ann Hematol. 2009 Nov;88(11):1059-67. (PMID: 19290526) Haematologica. 2020 Jul 03;105(9):2205-2217. (PMID: 33054046) Acta Haematol. 1996;95(3-4):257-62. (PMID: 8677752) J Coll Physicians Surg Pak. 2019 Jul;29(7):631-634. (PMID: 31253213) Blood. 2011 Feb 10;117(6):1928-37. (PMID: 21135257) Expert Rev Hematol. 2008 Oct;1(1):29-39. (PMID: 21083005) Mol Cancer Res. 2015 Jun;13(6):982-92. (PMID: 25944917) Cancers (Basel). 2019 Nov 21;11(12):. (PMID: 31766351) Expert Rev Anticancer Ther. 2018 Dec;18(12):1249-1270. (PMID: 30259761) Blood. 2001 Jan 1;97(1):89-94. (PMID: 11133746) Drug Resist Updat. 2009 Feb-Apr;12(1-2):8-16. (PMID: 19162530) Onco Targets Ther. 2013;6:99-106. (PMID: 23493838) Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):50-3. (PMID: 21454190) Br J Pharmacol. 2015 Jun;172(11):2675-700. (PMID: 25630872) Oncogene. 2011 Aug 11;30(32):3477-88. (PMID: 21577205) Pharmacol Res. 2016 Jan;103:26-48. (PMID: 26529477) Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8283-8. (PMID: 12060771) Trends Pharmacol Sci. 2014 Aug;35(8):414-22. (PMID: 24975478) Drugs. 2019 Feb;79(3):331-339. (PMID: 30721452) Int J Med Sci. 2004;1(2):101-115. (PMID: 15912202) Blood. 2003 Jun 15;101(12):4667-79. (PMID: 12623839) Oncogene. 2002 May 13;21(21):3314-33. (PMID: 12032772) Clin Cancer Res. 2008 Jan 15;14(2):396-404. (PMID: 18223214) J Cell Sci. 2002 Mar 1;115(Pt 5):1059-72. (PMID: 11870224) Drugs. 2018 Jan;78(1):139-145. (PMID: 29209955) Blood. 2008 May 1;111(9):4809-12. (PMID: 18160671) J Biol Chem. 1992 Feb 15;267(5):3262-7. (PMID: 1737782) Cancer Res. 1996 Aug 1;56(15):3589-96. (PMID: 8758931) Blood. 1992 Sep 1;80(5):1199-206. (PMID: 1381238) Blood. 2006 Aug 1;108(3):1030-6. (PMID: 16861351) J Clin Oncol. 2002 Mar 15;20(6):1692-703. (PMID: 11896121) Leukemia. 2020 Mar;34(3):787-798. (PMID: 31628428) Blood. 2006 Dec 1;108(12):3654-61. (PMID: 16912228) Curr Hematol Malig Rep. 2009 Apr;4(2):77-82. (PMID: 20425418) Leukemia. 1998 Sep;12(9):1375-82. (PMID: 9737685) Blood. 2008 May 1;111(9):4797-808. (PMID: 18270328) Cell. 1994 Apr 22;77(2):307-16. (PMID: 8168137) J Clin Oncol. 2006 Sep 10;24(26):4340-6. (PMID: 16908931) Blood. 2018 May 31;131(22):2454-2465. (PMID: 29650799) Leukemia. 2008 Oct;22(10):1966-9. (PMID: 18754031) Blood. 2001 Apr 15;97(8):2434-9. (PMID: 11290608) Nature. 2001 May 17;411(6835):355-65. (PMID: 11357143) J Exp Med. 2008 Apr 14;205(4):751-8. (PMID: 18362173) Pathol Oncol Res. 2014 Oct;20(4):901-7. (PMID: 24764074) Science. 1997 Nov 14;278(5341):1309-12. (PMID: 9360930) Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12950-5. (PMID: 19651600) Nat Rev Immunol. 2013 Aug;13(8):578-91. (PMID: 23883968) Nat Rev Cancer. 2007 Sep;7(9):673-83. (PMID: 17721432) Curr Hematol Malig Rep. 2019 Oct;14(5):395-404. (PMID: 31463864) Leukemia. 2015 Sep;29(9):1939-42. (PMID: 25676420) Front Pediatr. 2017 Nov 20;5:248. (PMID: 29209600) Cancer Metastasis Rev. 2012 Jun;31(1-2):295-321. (PMID: 22366781) J Hematol Oncol. 2015 Jul 26;8:91. (PMID: 26208852) Curr Hematol Malig Rep. 2006 Jun;1(2):101-7. (PMID: 20425339) Drugs. 2014 Feb;74(2):263-71. (PMID: 24464309) Leukemia. 2005 Apr;19(4):513-23. (PMID: 15703780) Genes Chromosomes Cancer. 2001 Apr;30(4):410-5. (PMID: 11241795) Leuk Lymphoma. 1999 Apr;33(3-4):371-6. (PMID: 10221518) Drugs. 2017 Jul;77(11):1251-1259. (PMID: 28612232) Proc Natl Acad Sci U S A. 2009 May 26;106(21):8695-700. (PMID: 19433805) Mol Cancer. 2018 Feb 19;17(1):48. (PMID: 29455673) Annu Rev Biochem. 1985;54:897-930. (PMID: 2992362) Blood Cancer J. 2017 Jan 6;6(1):e513. (PMID: 28060374) Sci Rep. 2019 Dec 9;9(1):18630. (PMID: 31819100) Drugs. 2020 Jan;80(1):91-97. (PMID: 31933167) Biochemistry. 2009 Oct 20;48(41):9823-30. (PMID: 19743875) Blood. 2008 May 1;111(9):4788-96. (PMID: 18252861) Cancer Discov. 2012 Jul;2(7):591-7. (PMID: 22705984) Nature. 1983 Nov 17-23;306(5940):277-80. (PMID: 6580527) Science. 1986 Aug 22;233(4766):859-66. (PMID: 3755548) PLoS One. 2019 Dec 2;14(12):e0225887. (PMID: 31790499) Leukemia. 2003 May;17(5):883-6. (PMID: 12750701) Blood. 2013 Sep 12;122(11):1900-13. (PMID: 23896410) Br J Haematol. 2005 Jul;130(1):58-66. (PMID: 15982345) Cell Mol Life Sci. 2009 Apr;66(7):1163-77. (PMID: 19011754) Clin Cancer Res. 2005 Oct 15;11(20):7209-19. (PMID: 16243790) Oncotarget. 2015 Jul 30;6(21):18250-64. (PMID: 26158763) Leukemia. 2016 Nov;30(11):2245-2247. (PMID: 27389054) Annu Rev Pharmacol Toxicol. 2015;55:465-87. (PMID: 25292427) Int J Mol Sci. 2019 Jul 12;20(14):. (PMID: 31336846) EMBO J. 1994 Mar 15;13(6):1341-9. (PMID: 8137818) N Engl J Med. 2006 Jan 12;354(2):166-78. (PMID: 16407512) Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1415-20. (PMID: 9990038) Biochemistry. 1984 Oct 9;23(21):5036-41. (PMID: 6238627) J Clin Invest. 1993 Oct;92(4):1736-44. (PMID: 7691885) Leuk Res. 2009 Dec;33(12):1623-6. (PMID: 19487028) Haematologica. 2015 Oct;100(10):1301-10. (PMID: 26206799) Biomark Res. 2018 Feb 13;6:8. (PMID: 29456860) J Hematol Oncol. 2018 Jan 05;11(1):3. (PMID: 29301553) Semin Immunol. 1995 Aug;7(4):267-77. (PMID: 8520031) Leuk Res. 2014 Dec;38(12):1435-40. (PMID: 25449688) Cancer Gene Ther. 2020 Feb;27(1-2):81-88. (PMID: 31285539) JAMA Oncol. 2020 Apr 1;6(4):542-546. (PMID: 31999305) N Engl J Med. 2015 Sep 17;373(12):1136-52. (PMID: 26376137) Blood Adv. 2017 Aug 28;1(20):1635-1644. (PMID: 29296810) Blood. 2003 Aug 15;102(4):1474-9. (PMID: 12702504) Mol Cancer. 2018 Feb 19;17(1):31. (PMID: 29455667) Oncotarget. 2016 Aug 2;7(31):50027-50042. (PMID: 27418135) Ann Pharmacother. 2013 Nov;47(11):1540-6. (PMID: 24265264) Blood. 2012 Mar 22;119(12):2883-94. (PMID: 22323452) Cell Commun Signal. 2012 Jul 17;10(1):21. (PMID: 22805580) Leuk Res. 2009 Mar;33(3):395-406. (PMID: 18819711) Cell Death Dis. 2020 Nov 6;11(11):956. (PMID: 33159047) Leuk Lymphoma. 2015 Mar;56(3):577-86. (PMID: 24898666) Br J Dermatol. 2018 Jan;178(1):26-27. (PMID: 29357585) J Clin Oncol. 2004 Sep 15;22(18):3813-25. (PMID: 15365079) Expert Opin Investig Drugs. 2012 Apr;21(4):409-23. (PMID: 22409342) Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1611-5. (PMID: 1311845) Blood Cancer J. 2017 Jun 30;7(6):e577. (PMID: 28665419) Leuk Lymphoma. 1996 Nov;23(5-6):459-65. (PMID: 9031076) Crit Rev Oncol Hematol. 2007 Sep;63(3):215-30. (PMID: 17658267) Mol Cancer. 2018 Feb 19;17(1):58. (PMID: 29455648) Curr Opin Hematol. 2002 Jul;9(4):274-81. (PMID: 12042700) Matrix Biol. 2014 Feb;34:185-92. (PMID: 24361528) Leukemia. 1999 Jan;13(1):38-43. (PMID: 10049058) Clin Cancer Res. 2002 Oct;8(10):3034-8. (PMID: 12374669) Haematologica. 2015 Oct;100(10):1240-53. (PMID: 26432382) Leukemia. 2012 Nov;26(11):2360-6. (PMID: 22705992) BMC Bioinformatics. 2017 Jan 5;18(1):16. (PMID: 28056780) Blood. 2002 Jan 1;99(1):310-8. (PMID: 11756186) Chem Biol Drug Des. 2020 Oct 9;:. (PMID: 33034143) Ann Pharmacother. 2015 Oct;49(10):1162-70. (PMID: 26185276) Exp Hematol. 2017 Oct;54:31-39. (PMID: 28751189) Clin Colorectal Cancer. 2010 Apr;9(2):89-94. (PMID: 20378502) Cancer Res. 2009 Jul 1;69(13):5424-32. (PMID: 19549911) Bioorg Med Chem Lett. 2009 Feb 15;19(4):1240-4. (PMID: 19155174) Sci Rep. 2017 Nov 7;7(1):14767. (PMID: 29116180) Oncogene. 2013 May 23;32(21):2601-13. (PMID: 22869151) Blood. 2011 Oct 20;118(16):4313-20. (PMID: 21816833) Cancers (Basel). 2018 Mar 01;10(3):. (PMID: 29494549) Blood. 2009 Mar 12;113(11):2508-16. (PMID: 18981293) Blood. 2010 Dec 9;116(24):5089-102. (PMID: 20705759) Nephron. 2017;137(3):212-220. (PMID: 28743124) N Engl J Med. 2001 Apr 5;344(14):1031-7. (PMID: 11287972) Blood. 1991 Dec 1;78(11):2962-8. (PMID: 1720040) Blood. 2008 Feb 15;111(4):2269-79. (PMID: 18056483) Cell. 2011 Oct 28;147(3):554-64. (PMID: 22036564) Nat Genet. 2004 May;36(5):453-61. (PMID: 15098032) J Biol Chem. 2010 Feb 19;285(8):5296-307. (PMID: 20028972) Oncogene. 2000 Nov 20;19(49):5548-57. (PMID: 11114734) Circulation. 2004 Mar 16;109(10):1196-205. (PMID: 15023894) Biochim Biophys Acta Mol Basis Dis. 2017 Feb;1863(2):450-461. (PMID: 27840303) Cancer Cell. 2009 Oct 6;16(4):281-94. (PMID: 19800574) Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14442-7. (PMID: 17726105) Oncogene. 2009 Sep 17;28(37):3261-73. (PMID: 19581935) Am J Hematol. 2018 Mar;93(3):442-459. (PMID: 29411417) Oncogene. 2000 Nov 20;19(49):5662-79. (PMID: 11114747) J Hematol Oncol. 2018 Jun 20;11(1):84. (PMID: 29925402) Blood. 2008 Aug 1;112(3):721-32. (PMID: 18385452) Curr Oncol. 2019 Apr;26(2):e233-e240. (PMID: 31043832) Blood. 1996 Feb 1;87(3):1089-96. (PMID: 8562934) Biochim Biophys Acta. 1996 Aug 8;1288(1):M7-10. (PMID: 8764840) Clin Cancer Res. 2004 Feb 15;10(4):1241-9. (PMID: 14977821) Br J Haematol. 2006 Feb;132(3):303-16. (PMID: 16409295) Expert Rev Hematol. 2014 Aug;7(4):439-64. (PMID: 25025370) Blood. 2010 Apr 1;115(13):2578-85. (PMID: 19965662) |
| فهرسة مساهمة: | Keywords: leukaemia; non-receptor tyrosine kinase; protein kinase; receptor tyrosine kinase; small molecule inhibitor; therapeutic antibodies |
| تواريخ الأحداث: | Date Created: 20210112 Latest Revision: 20210126 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC7825731 |
| DOI: | 10.3390/cancers13020184 |
| PMID: | 33430292 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2072-6694 |
|---|---|
| DOI: | 10.3390/cancers13020184 |